Skip to main content
Erschienen in: Current Pain and Headache Reports 4/2010

01.08.2010

Substance Abuse in Cancer Pain

verfasst von: Tatiana D. Starr, Lauren J. Rogak, Steven D. Passik

Erschienen in: Current Pain and Headache Reports | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

In the oncology community, opioids recently have become the cornerstone of cancer pain management. This has led to a rapid increase in opioid prescribing in an effort to address the growing public health problem of chronic pain. A new paradigm in noncancer pain management has emerged, that of risk assessment and stratification in opioid therapy. Techniques foreign to cancer pain management have now become commonplace in the noncancer pain setting, such as the use of monitoring compliance via urine drug screens. Amidst these strides in opioid use for pain management, cancer has been changing. The survival rate has increased, and a group of these patients with chronic pain were treated with opioid therapy. With opioid exposure being longer and against the backdrop of prescription drug abuse, the question is how much of the adaptation of the risk management paradigm in chronic pain management is to be imported to cancer pain management?
Literatur
1.
Zurück zum Zitat •• Passik SD, Kirsh KL: Forget the recipes: let’s talk data. Pain Medicine 2008, 9:261–265. This article describes the ongoing debate in opioid prescribing in patients with cancer and noncancer chronic pain. Specifically, it highlights the need for risk assessment and individually tailored treatment regimens depending on a patient’s level of risk for opioid abuse. It also discusses important considerations for managing breakthrough pain.CrossRef •• Passik SD, Kirsh KL: Forget the recipes: let’s talk data. Pain Medicine 2008, 9:261–265. This article describes the ongoing debate in opioid prescribing in patients with cancer and noncancer chronic pain. Specifically, it highlights the need for risk assessment and individually tailored treatment regimens depending on a patient’s level of risk for opioid abuse. It also discusses important considerations for managing breakthrough pain.CrossRef
2.
Zurück zum Zitat Passik SD, Olden M, Kirsh KL, Portenoy RK: Substance abuse issues in palliative care. In Principles and Practice of Palliative Care and Supportive Oncology, edn 3. Edited by Berger AM, Portenoy RK, Weissman DE. Philadelphia: Lippincott Williams & Wilkins; 2007:593–603. Passik SD, Olden M, Kirsh KL, Portenoy RK: Substance abuse issues in palliative care. In Principles and Practice of Palliative Care and Supportive Oncology, edn 3. Edited by Berger AM, Portenoy RK, Weissman DE. Philadelphia: Lippincott Williams & Wilkins; 2007:593–603.
3.
Zurück zum Zitat Burton RW, Lyons JS, Devens M, Larson DB: Psychiatric consultations for psychoactive substance disorders in the general hospital. Gen Hosp Psychiatry 1991, 13:83–87.CrossRefPubMed Burton RW, Lyons JS, Devens M, Larson DB: Psychiatric consultations for psychoactive substance disorders in the general hospital. Gen Hosp Psychiatry 1991, 13:83–87.CrossRefPubMed
4.
Zurück zum Zitat Colliver JD, Kopstein AN: Trends in cocaine abuse reflected in emergency room episodes reported to DAWN. Drug Abuse Warning Network. Public Health Rep 1991, 106:59–68.PubMed Colliver JD, Kopstein AN: Trends in cocaine abuse reflected in emergency room episodes reported to DAWN. Drug Abuse Warning Network. Public Health Rep 1991, 106:59–68.PubMed
5.
Zurück zum Zitat Derogatis LR, Morrow GR, Fetting J, et al.: The prevalence of psychiatric disorders among cancer patients. JAMA 1983, 249:751–757.CrossRefPubMed Derogatis LR, Morrow GR, Fetting J, et al.: The prevalence of psychiatric disorders among cancer patients. JAMA 1983, 249:751–757.CrossRefPubMed
6.
Zurück zum Zitat Gfroerer J, Brodsky M: The incidence of illicit drug use in the United States, 1962–1989. Br J Addict 1992, 87:1345–1351.CrossRefPubMed Gfroerer J, Brodsky M: The incidence of illicit drug use in the United States, 1962–1989. Br J Addict 1992, 87:1345–1351.CrossRefPubMed
7.
Zurück zum Zitat Regier DA, Myers JK, Kramer M, et al.: The NIMH Epidemiologic Catchment Area program. Historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984, 41:934–941.PubMed Regier DA, Myers JK, Kramer M, et al.: The NIMH Epidemiologic Catchment Area program. Historical context, major objectives, and study population characteristics. Arch Gen Psychiatry 1984, 41:934–941.PubMed
8.
Zurück zum Zitat American Psychiatric Association: Diagnostic and Statistical Manual for Mental Disorders, edn 3. Washington DC: American Psychiatric Association; 1983. American Psychiatric Association: Diagnostic and Statistical Manual for Mental Disorders, edn 3. Washington DC: American Psychiatric Association; 1983.
9.
Zurück zum Zitat Kirsh KL, Whitcomb LA, Donaghy L, Passik SD: Abuse and addiction issues in medically ill patients with pain: Attempts at clarification of terms and empirical study. Clin J Pain 2002, 18(4 Suppl):S52–S60.CrossRefPubMed Kirsh KL, Whitcomb LA, Donaghy L, Passik SD: Abuse and addiction issues in medically ill patients with pain: Attempts at clarification of terms and empirical study. Clin J Pain 2002, 18(4 Suppl):S52–S60.CrossRefPubMed
13.
Zurück zum Zitat Cleeland CS, Ryan KM: Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994, 23:129–138.PubMed Cleeland CS, Ryan KM: Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994, 23:129–138.PubMed
14.
Zurück zum Zitat Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16:606–613.CrossRefPubMed Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001, 16:606–613.CrossRefPubMed
15.
Zurück zum Zitat Stratford PW, Binkley J, Solomon P, et al.: Defining the minimum level of detectable change for the Roland-Morris questionnaire. Phys Ther 1996, 76:359–365.PubMed Stratford PW, Binkley J, Solomon P, et al.: Defining the minimum level of detectable change for the Roland-Morris questionnaire. Phys Ther 1996, 76:359–365.PubMed
16.
Zurück zum Zitat •• Passik SD, Kirsh KL: The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse. Exp Clin Psychopharmacol 2008, 16:400–404. This important review highlights the need to screen patients with chronic pain for addiction and abuse risk throughout the duration of pain management, including even before initiation of opioid therapy.CrossRefPubMed •• Passik SD, Kirsh KL: The interface between pain and drug abuse and the evolution of strategies to optimize pain management while minimizing drug abuse. Exp Clin Psychopharmacol 2008, 16:400–404. This important review highlights the need to screen patients with chronic pain for addiction and abuse risk throughout the duration of pain management, including even before initiation of opioid therapy.CrossRefPubMed
17.
Zurück zum Zitat Akbik H, Butler SF, Budman SH, et al.: Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage 2006, 32:287–293.CrossRefPubMed Akbik H, Butler SF, Budman SH, et al.: Validation and clinical application of the Screener and Opioid Assessment for Patients with Pain (SOAPP). J Pain Symptom Manage 2006, 32:287–293.CrossRefPubMed
18.
Zurück zum Zitat Butler SF, Budman SH, Fernandez K, Jamison RN: Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004, 112:65–75.CrossRefPubMed Butler SF, Budman SH, Fernandez K, Jamison RN: Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004, 112:65–75.CrossRefPubMed
19.
Zurück zum Zitat Webster LR, Webster RM: Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005, 6:432–442.CrossRefPubMed Webster LR, Webster RM: Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005, 6:432–442.CrossRefPubMed
20.
Zurück zum Zitat Passik SD, Weinreb HJ: Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther 2000, 17:70–83.CrossRefPubMed Passik SD, Weinreb HJ: Managing chronic nonmalignant pain: overcoming obstacles to the use of opioids. Adv Ther 2000, 17:70–83.CrossRefPubMed
21.
Zurück zum Zitat Passik SD, Kirsh KL, McDonald MV, et al.: A pilot survey of aberrant drug-taking attitudes and behaviors in samples of cancer and AIDS patients. J Pain Symptom Manage 2000, 19:274–286.CrossRefPubMed Passik SD, Kirsh KL, McDonald MV, et al.: A pilot survey of aberrant drug-taking attitudes and behaviors in samples of cancer and AIDS patients. J Pain Symptom Manage 2000, 19:274–286.CrossRefPubMed
22.
Zurück zum Zitat Portenoy RK, Lussier D, Kirsh KL, Passik SD: Pain and addiction. In Clinical Textbook of Addictive Disorders, edn 3. Edited by Frances RJ, Miller SI, Mack AH. New York: Guilford Press; 2005:367–395. Portenoy RK, Lussier D, Kirsh KL, Passik SD: Pain and addiction. In Clinical Textbook of Addictive Disorders, edn 3. Edited by Frances RJ, Miller SI, Mack AH. New York: Guilford Press; 2005:367–395.
23.
Zurück zum Zitat Passik SD, Kirsh KL: Managing pain in patients with aberrant drug-taking behaviors. J Support Oncol 2005, 3:83–86.PubMed Passik SD, Kirsh KL: Managing pain in patients with aberrant drug-taking behaviors. J Support Oncol 2005, 3:83–86.PubMed
24.
Zurück zum Zitat Passik SD, Kirsh KL, Whitcomb L, et al.: A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther 2004, 26:552–561.CrossRefPubMed Passik SD, Kirsh KL, Whitcomb L, et al.: A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther 2004, 26:552–561.CrossRefPubMed
25.
26.
Zurück zum Zitat Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, Pappagallo M: Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage 1998, 15:185–194.CrossRefPubMed Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, Pappagallo M: Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage 1998, 15:185–194.CrossRefPubMed
27.
Zurück zum Zitat Raja SN, Haythornthwaite JA, Pappagallo M, et al.: Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002, 59:1015–1021.PubMed Raja SN, Haythornthwaite JA, Pappagallo M, et al.: Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002, 59:1015–1021.PubMed
28.
Zurück zum Zitat Weissman DE, Haddox JD: Opioid pseudoaddiction—an iatrogenic syndrome. Pain 1989, 36:363–366.CrossRefPubMed Weissman DE, Haddox JD: Opioid pseudoaddiction—an iatrogenic syndrome. Pain 1989, 36:363–366.CrossRefPubMed
29.
Zurück zum Zitat Pappagallo M: The concept of pseudotolerance to opioids. J Pharm Care Pain Symptom Control 1998, 6:95–98.CrossRef Pappagallo M: The concept of pseudotolerance to opioids. J Pharm Care Pain Symptom Control 1998, 6:95–98.CrossRef
30.
Zurück zum Zitat Smith HS: Variations in opioid responsiveness. Pain Physician 2008, 11:237–248.PubMed Smith HS: Variations in opioid responsiveness. Pain Physician 2008, 11:237–248.PubMed
31.
Zurück zum Zitat Smith HS, Deer TR, Staats PS, et al.: Intrathecal drug delivery. Pain Physician 2008, 11(2 Suppl):S89–S104.PubMed Smith HS, Deer TR, Staats PS, et al.: Intrathecal drug delivery. Pain Physician 2008, 11(2 Suppl):S89–S104.PubMed
32.
Zurück zum Zitat Bennett D, Burton AW, Fishman S, et al.: Consensus panel recommendations for the assessment and management of breakthrough pain: Part 1 Assessment. P and T 2005, 30:296–301. Bennett D, Burton AW, Fishman S, et al.: Consensus panel recommendations for the assessment and management of breakthrough pain: Part 1 Assessment. P and T 2005, 30:296–301.
33.
Zurück zum Zitat Zeppetella G: Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 2008, 35:563–567.CrossRefPubMed Zeppetella G: Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage 2008, 35:563–567.CrossRefPubMed
34.
Zurück zum Zitat Caraceni A, Martini C, Zecca E, et al.: Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004, 18:177–183.CrossRefPubMed Caraceni A, Martini C, Zecca E, et al.: Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004, 18:177–183.CrossRefPubMed
35.
Zurück zum Zitat Fortner BV, Demarco G, Irving G, et al.: Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage 2003, 25:9–18.CrossRefPubMed Fortner BV, Demarco G, Irving G, et al.: Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage 2003, 25:9–18.CrossRefPubMed
36.
Zurück zum Zitat Portenoy RK, Payne D, Jacobsen P: Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999, 81:129–134.CrossRefPubMed Portenoy RK, Payne D, Jacobsen P: Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999, 81:129–134.CrossRefPubMed
37.
Zurück zum Zitat Fine PG, Busch MA: Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage 1998, 16:179–183.CrossRefPubMed Fine PG, Busch MA: Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage 1998, 16:179–183.CrossRefPubMed
38.
Zurück zum Zitat Hwang SS, Chang VT, Kasimis B: Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003, 101(1–2):55–64.CrossRefPubMed Hwang SS, Chang VT, Kasimis B: Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 2003, 101(1–2):55–64.CrossRefPubMed
39.
Zurück zum Zitat Mercadante S, Radbruch L, Caraceni A, et al.: Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002, 94:832–839.CrossRefPubMed Mercadante S, Radbruch L, Caraceni A, et al.: Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002, 94:832–839.CrossRefPubMed
40.
Zurück zum Zitat Portenoy RK, Hagen NA: Breakthrough pain: definition, prevalence and characteristics. Pain 1990, 41:273–281.CrossRefPubMed Portenoy RK, Hagen NA: Breakthrough pain: definition, prevalence and characteristics. Pain 1990, 41:273–281.CrossRefPubMed
41.
Zurück zum Zitat Svendsen KB, Andersen S, Arnason S, et al.: Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005, 9:195–206.CrossRefPubMed Svendsen KB, Andersen S, Arnason S, et al.: Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 2005, 9:195–206.CrossRefPubMed
43.
Zurück zum Zitat Fortner BV, Okon TA, Portenoy RK: A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002, 3:38–44.CrossRefPubMed Fortner BV, Okon TA, Portenoy RK: A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002, 3:38–44.CrossRefPubMed
44.
Zurück zum Zitat Bruera E, Schoeller T, Wenk R, et al.: A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage 1995, 10:348–355.CrossRefPubMed Bruera E, Schoeller T, Wenk R, et al.: A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage 1995, 10:348–355.CrossRefPubMed
45.
Zurück zum Zitat Mercadante S, Maddaloni S, Roccella S, Salvaggio L: Predictive factors in advanced cancer pain treated only by analgesics. Pain 1992, 50:151–155.CrossRefPubMed Mercadante S, Maddaloni S, Roccella S, Salvaggio L: Predictive factors in advanced cancer pain treated only by analgesics. Pain 1992, 50:151–155.CrossRefPubMed
46.
Zurück zum Zitat Bennett D, Burton AW, Fishman S, et al.: Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2. Management. P T 2005, 30:354–361. Bennett D, Burton AW, Fishman S, et al.: Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2. Management. P T 2005, 30:354–361.
47.
Zurück zum Zitat Eichman JD, Robinson JR: Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res 1998, 15:925–930.CrossRefPubMed Eichman JD, Robinson JR: Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res 1998, 15:925–930.CrossRefPubMed
48.
Zurück zum Zitat Durfee S, Messina J, Khankari RK: Fentanyl effervescent buccal tablets. Am J Drug Deliv 2006, 4:1–5.CrossRef Durfee S, Messina J, Khankari RK: Fentanyl effervescent buccal tablets. Am J Drug Deliv 2006, 4:1–5.CrossRef
49.
Zurück zum Zitat Coluzzi PH, Schwartzberg L, Conroy JD, et al.: Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001, 91:123–130.CrossRefPubMed Coluzzi PH, Schwartzberg L, Conroy JD, et al.: Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain 2001, 91:123–130.CrossRefPubMed
51.
Zurück zum Zitat Banning A, Sjogren P, Henriksen H: Treatment outcome in a multidisciplinary cancer pain clinic. Pain 1991, 47:129–134.CrossRefPubMed Banning A, Sjogren P, Henriksen H: Treatment outcome in a multidisciplinary cancer pain clinic. Pain 1991, 47:129–134.CrossRefPubMed
52.
Zurück zum Zitat McQuay HJ, Jadad AR: Incident pain. Cancer Surv 1994, 21:17–24.PubMed McQuay HJ, Jadad AR: Incident pain. Cancer Surv 1994, 21:17–24.PubMed
Metadaten
Titel
Substance Abuse in Cancer Pain
verfasst von
Tatiana D. Starr
Lauren J. Rogak
Steven D. Passik
Publikationsdatum
01.08.2010
Verlag
Current Science Inc.
Erschienen in
Current Pain and Headache Reports / Ausgabe 4/2010
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI
https://doi.org/10.1007/s11916-010-0118-6

Weitere Artikel der Ausgabe 4/2010

Current Pain and Headache Reports 4/2010 Zur Ausgabe

ReviewPaper

Fasting Headache

ReviewPaper

Hypnic Headache

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.